KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Common Equity (2016 - 2025)

Historic Common Equity for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Q3 2025 value amounting to $6.1 billion.

  • Biomarin Pharmaceutical's Common Equity rose 1188.38% to $6.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $6.1 billion, marking a year-over-year increase of 1188.38%. This contributed to the annual value of $5.7 billion for FY2024, which is 1426.71% up from last year.
  • As of Q3 2025, Biomarin Pharmaceutical's Common Equity stood at $6.1 billion, which was up 1188.38% from $6.0 billion recorded in Q2 2025.
  • Biomarin Pharmaceutical's 5-year Common Equity high stood at $6.1 billion for Q3 2025, and its period low was $4.2 billion during Q1 2021.
  • For the 5-year period, Biomarin Pharmaceutical's Common Equity averaged around $4.9 billion, with its median value being $4.8 billion (2023).
  • Data for Biomarin Pharmaceutical's Common Equity shows a peak YoY increase of 3104.7% (in 2021) and a maximum YoY decrease of 388.86% (in 2021) over the last 5 years.
  • Biomarin Pharmaceutical's Common Equity (Quarter) stood at $4.3 billion in 2021, then rose by 7.91% to $4.6 billion in 2022, then increased by 7.57% to $5.0 billion in 2023, then grew by 14.27% to $5.7 billion in 2024, then rose by 7.05% to $6.1 billion in 2025.
  • Its Common Equity was $6.1 billion in Q3 2025, compared to $6.0 billion in Q2 2025 and $5.8 billion in Q1 2025.